Nonalcoholic steatohepatitis (NASH) is liver inflammation and
damage caused by a buildup of fat in the liver. It is also known as silent
liver disease. It is a type of nonalcoholic fatty liver disease (NAFLD), which
mainly affects people with diabetes and obesity. Nonalcoholic Steatohepatitis
(NASH) is defined by histological hallmarks of inflammation, hepatic steatosis,
cell death, and fibrosis. A number of drugs used to treat medical
situation have been NASH, such as amiodarone (Corderone, Pacerone), tamoxifen
(Nolvadex), perhexiline maleate (Pexhid) and steroids (eg, prednisone). Medical
studies have identified a strong connection of NASH with certain risk factors
such as insulin resistance, oxidative stress and release of toxic inflammatory
proteins.
Nonalcoholic steatohepatitis is a gradually becoming common
chronic liver disease around the world and is closely related with diabetes and
obesity. Rising incidence of NAFLD cases, changing lifestyle patterns,
increasing rate of obesity and diabetes, and initiatives for research and
development are the major driving factors of this market. However, insufficient
information about the pathophysiology of NASH tissue and ineffective diagnostic
technology for NASH is considered to restraint in this market.
Get Full Detail @ http://www.syndicatemarketresearch.com/market-analysis/nonalcoholic-steatohepatitis-market.html
The report includes detailed competitive landscape of the global
nonalcoholic steatohepatitis market and an analysis of Porter’s five forces
model for the nonalcoholic steatohepatitis market has also been included. It
includes company market share analysis, product portfolio of the major industry
participants. The report provides detailed segmentation of the nonalcoholicsteatohepatitis market based on drugs type and region segment. GFT505,
Obeticholic Acid (INT-747), Simtuzumab and Liraglutide (Victoza), Vitamin E,
Poglitazone, Placebo is the drug type segment of nonalcoholic steatohepatitis
market.
Major regional segments analyzed in this study include North
America, Europe, Asia Pacific, Latin America, and Middle East and Africa with
its further bifurcation into major countries including U.S., Germany, France,
UK, China, Japan, India, and Brazil. This segmentation includes demand
for nonalcoholic steatohepatitis based on individual products and applications
in all the regions and countries. The nonalcoholic steatohepatitis market is
dominated by North America followed by Asia Pacific. Asia pacific is expected
to the fastest growing segment in the forecast period.
Get Request Sample
@ http://www.syndicatemarketresearch.com/request-for-sample.html?flag=S&repid=52719
The report covers detailed competitive outlook including company
profiles of the key participants operating in the global market. Key players
profiled in the report include Intercepts Pharmaceuticals, Exalenz Bioscience
Inc., Galectin Therapeutics Inc., Genfit, Gilead Science, AstraZeneca
plc, Echosense SA, Raptor Pharmaceutical Corp, Matinas Biopharma Holdings
Inc., Enzo Biochem, Inc., Galmed Pharmaceuticals Ltd., Perspectum
Diagnostics and Novo Nordisk.
This report segments the global nonalcoholic steatohepatitismarket as follows:
Global Nonalcoholic Steatohepatitis Market: Drug Type Segment
Analysis
- GFT505
- Obeticholic
Acid (INT-747)
- Simtuzumab
and Liraglutide (Victoza)
- Vitamin
E
- Poglitazone
- Placebo
Global Nonalcoholic Steatohepatitis Market: Regional Segment
Analysis
- North
America
- U.S.
- Europe
- UK
- France
- Germany
- Asia
Pacific
- China
- Japan
- India
- Latin
America
- Brazil
- Middle
East And Africa
Contact US:
No comments:
Post a Comment